Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation

Eur J Cancer. 2022 Apr:165:154-156. doi: 10.1016/j.ejca.2022.02.001. Epub 2022 Feb 27.

¹ Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
² Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China; Human Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, 410011, Hunan, China; Human Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China; Human Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. Electronic address: wufang4461@csu.edu.cn.

No abstract available

Publication types